References
- Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 2006; 4: 9–25
- Zhanel GG, Homenuik K, Nichol K, Noreddin A, Vercaigne L, Embil J, et al. The glycylcyclines, a comparative review with the tetracyclines. Drugs 2004; 64: 63–88
- Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam, in patients with complicated skin and skin-structure infections: results from a phase III randomized double-blind trial. Int J Infect Dis 2005; 9: 251–61
- Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasnaand T, Ross DP, et al. Safety and efficacy of tigecycline in treatment of sin and skin-structure infections: results of a double-blind phase III comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005; 49: 4658–66
- Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase III comparison studies with vancomycin-aztreonam. Clin Inf Dis 2005; 41(Suppl 5)S341–53
- Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005; 49: 220–9
- Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of antibacterial resistance. Microbiol Mol Biol Rev 2001; 65: 232–60
- Greer ND. Tigecycline (Tigacyl): the first in the glycylcycline class of antibiotics. Proc (Bayl Univ Med Cent) 2006; 19: 155–61
- Unpublished observations. Tygacyl, Second Periodic Safety Update Report-Preliminary assessment report. Rapporteur: Calvo G. Pharmacovigilance assessors: Macia MA, Martin-Serrano G. Clinical assessor: Fernandez-Cortizo MJ. Period covered by this PSUR: 15 Jun 2006 to 14 December 2006. Date of the assessment report: 17 April 2007.